Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

746
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
746
Therapeutic Index01:13

Therapeutic Index

7.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of routinely tailoring anti-hypertensive therapy to hemodynamic profile in primary care.

The American journal of medicine·2026
Same author

Health Resources and Services Administration and Veterans Affairs Funding Intersections Expand Graduate Medical Education Training Opportunities in Rural and Underserved Areas.

The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association·2026
Same author

The Evolving Role of Critical Access Hospitals in Rural Physician Training.

JAMA health forum·2025
Same author

Comparing Indian Health Service Sites to Rural Physician Teaching Hospitals.

JAMA internal medicine·2025
Same author

Evaluating Teaching Health Center Planning and Development: Unlocking and Sustaining the Full Potential of the Teaching Health Center Program.

Journal of graduate medical education·2025
Same author

Faculty Development in New and Emerging Rural Residency Programs.

Journal of graduate medical education·2025

Related Experiment Video

Updated: Apr 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Anticoagulation: choosing the optimal anticoagulant.

Emily M Hawes1, Anthony J Viera2

  • 1UNC Chapel Hill Department of Family Medicine, 590 Manning Drive CB 7595, Chapel Hill, NC 27599, EHawes@unch.unc.edu.

FP Essentials
|July 18, 2014
PubMed
Summary

Anticoagulation therapy decisions require balancing bleeding and thrombosis risks. Guidelines recommend specific anticoagulants for atrial fibrillation, surgical prophylaxis, acute coronary syndrome, mechanical heart valves, and venous thromboembolism.

More Related Videos

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

7.9K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Related Experiment Videos

Last Updated: Apr 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

7.9K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Anticoagulation therapy is crucial for preventing thrombotic events but carries bleeding risks.
  • Patient-specific factors, including risk scores like CHADS2, guide treatment decisions.
  • Nonvalvular atrial fibrillation, surgical procedures, and specific cardiovascular conditions necessitate tailored anticoagulation strategies.

Purpose of the Study:

  • To outline current recommendations for initiating and managing anticoagulation therapy.
  • To provide guidance on selecting appropriate anticoagulant agents based on clinical indications and patient risk profiles.
  • To emphasize the importance of risk-benefit assessment in anticoagulation decisions.

Main Methods:

  • Review of clinical guidelines and evidence for anticoagulation therapy.
  • Analysis of indications for anticoagulation in various patient populations.
  • Comparison of different anticoagulant agents and their appropriate use cases.

Main Results:

  • Oral anticoagulation is recommended for nonvalvular atrial fibrillation patients with a CHADS2 score of 1 or higher, with options including apixaban, dabigatran, rivaroxaban, or warfarin.
  • Pharmacologic prophylaxis for hospitalized patients depends on thrombosis risk; high-risk patients receive heparin or fondaparinux, while low-risk patients do not.
  • Specific anticoagulation regimens are advised for nonorthopedic surgery, orthopedic surgery, acute coronary syndrome, mechanical heart valves, deep venous thrombosis, and pulmonary embolism.

Conclusions:

  • Therapeutic decisions for anticoagulation must carefully weigh the risks of bleeding against the benefits of preventing thrombosis.
  • A range of anticoagulant options are available, with selection dependent on the specific clinical scenario and patient characteristics.
  • Adherence to evidence-based guidelines ensures optimal patient outcomes in anticoagulation management.